newsfilter
← Latest News
GlobeNewswire·

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and